Market Place
Sourcing Support
Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting
17 Apr 2023 //
BUSINESSWIRE
Lundbeck`s Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.
21 Oct 2022 //
FDA
Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag
19 Aug 2022 //
FIERCEPHARMA
Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine
09 Jun 2022 //
BUSINESSWIRE
Lundbeck`s Vyepti (Eptinezumab) Receives Approval in Europe
15 Feb 2022 //
EMA
Lundbeck`s Biological Eptinezumab-Jjmr Receives Supplemental Approval In US
24 Sep 2021 //
FDA
The Journal of the AMA Publishes Data on Efficacy of VYEPTI
15 Jun 2021 //
BUSINESSWIRE
New Data Presented at 2021 American (AAN) Annual Meeting Shows VYEPTI®
19 Apr 2021 //
BUSINESSWIRE
Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study
31 Aug 2020 //
BIOSPACE
AHS Posters for Lundbeck’s VYEPTI™ (eptinezumab-jjmr) in Migraine Prevention
12 Jun 2020 //
BUSINESSWIRE
Orsini Pharmaceutical Services Selected To Provide VYEPTI™ (eptinezumab-jjmr)
22 Apr 2020 //
PR NEWSWIRE
Lundbeck aims to grow Vyepti in busy migraine prevention field
01 Apr 2020 //
FIERCE PHARMA
Lundbeck scores FDA nod in crowded migraine prevention field
25 Feb 2020 //
FIERCE PHARMA
Go or no go? Esperion`s double whammy and a look to priority reviews
31 Jan 2020 //
EVALUATE
Lundbeck didn’t just want an ex-US deal for Alder’s migraine drug
24 Sep 2019 //
ENDPTS
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations
08 Jul 2019 //
GLOBE NEWSWIRE
Amgen launches TV spot for Aimovig in tight CGRP market
17 Oct 2018 //
BIOPHARMA DIVE
Aimovig`s launch trends `bode well` for other CGRPs: analyst
21 Aug 2018 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.